Welcome to our dedicated page for Zai Lab news (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab stock.
Zai Lab Limited reports developments for a commercial-stage biopharmaceutical company with American depositary shares traded under ZLAB and ordinary shares listed in Hong Kong. The company discovers, develops, licenses and commercializes therapies for oncology, immunology, neuroscience and infectious disease, with operations based in China and the United States.
Recurring company updates include financial results, regulatory designations, clinical and preclinical data, collaborations and product updates across programs such as zocilurtatug pelitecan, ZL-1503, ZL-6201 and ZL-1222. Updates also address regional commercial products and pipeline assets including ZEJULA, VYVGART, KarXT and TIVDAK.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) presented new interim overall survival (OS) data for ZEJULA® (niraparib) in patients with platinum-sensitive recurrent ovarian cancer at the ESMO Virtual Plenary. The median overall survival was 46.3 months for ZEJULA compared to 43.4 months for placebo. Notably, the results suggest a favorable trend in OS regardless of gBRCA mutation status. No new safety concerns were identified in the study. The final OS analysis is anticipated in 2023, further establishing ZEJULA's role as a second-line maintenance therapy for ovarian cancer.
Zai Lab announced promising preliminary results for adagrasib combined with pembrolizumab in treating first-line advanced/metastatic NSCLC with KRASG12C mutation. Data from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort show favorable tolerability and an overall response rate (ORR) of 49%, with a notable 56% in a select subset. The safety profile revealed manageable treatment-related adverse events. This data will be presented on December 7 at the ESMO Immuno-Oncology Congress, highlighting the potential of this combination therapy for treatment-naïve patients.
Zai Lab reported third-quarter 2022 revenues of $57.5 million, marking a 33% year-on-year and 19% quarter-on-quarter increase. This growth is driven by the success of ZEJULA and a new collaboration for TIVDAK. The company maintains a strong balance sheet with $1.12 billion in cash, supporting operations through 2025. R&D expenses rose to $99.5 million, influenced by increased clinical trial costs and a $30 million upfront payment to Seagen. Despite these expenses, Zai Lab expects net product revenue to surpass costs in 2023.
Zai Lab Limited (NASDAQ: ZLAB) will present new data on its immuno-oncology pipeline at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 8-12, 2022, in Boston, Mass. The focus will be on two key programs: ZL-1211 (anti-CLDN18.2 antibody) for gastric cancer and ZL-1218 (anti-CCR8 antibody) for solid tumors. Presentations will feature research on enhancing anti-tumor activities and targeting intratumoral Treg subpopulations, showcasing Zai Lab's commitment to advancing its global R&D pipeline.
Zai Lab Limited (NASDAQ: ZLAB) has appointed Dr. Peter Huang as its new Chief Scientific Officer, effective immediately. Dr. Huang, with over 16 years in the biopharmaceutical sector, previously held senior roles at Zentalis Pharmaceuticals and Pfizer. He will lead Zai Lab's discovery efforts and translational medicine, aiming to advance the company’s innovative drug pipeline. Dr. Huang expressed enthusiasm about overseeing product development that addresses unmet medical needs both in China and globally.
Zai Lab Limited (NASDAQ: ZLAB) announced participation in upcoming investor conferences this November, including the Goldman Sachs Asia Pacific Healthcare Forum, Morgan Stanley Annual Asia Pacific Summit, Jefferies London Healthcare Conference, and the BioCentury-BayHelix East-West Summit. These events will feature panel discussions and meetings aimed at enhancing investor communication. Zai Lab focuses on developing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders.
Zai Lab Limited (NASDAQ: ZLAB) announced it will report financial results for Q3 2022 on November 9, 2022, after market close. A conference call and webcast will be held on November 10, 2022, at 8:00 a.m. ET, where the company will provide corporate updates. Investors can register in advance through the provided link. Zai Lab is committed to delivering innovative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders.
Zai Lab has launched its 2022 Trust Report, detailing its ESG strategy called 'Trust for Life.' The strategy encompasses three commitments: to improve human health, create better outcomes, and act right now. Aiming to reach one million patients by 2030, Zai Lab emphasizes diversity within its workforce, with women representing 58% of employees. The company has also achieved base pay equity and aims for net zero greenhouse gas emissions. Notably, Zai's sustainability efforts received a score of 41 from S&P Global, reflecting a 27-point improvement from 2021.
Zai Lab has secured exclusive rights to develop and commercialize TIVDAK, an FDA-approved antibody-drug conjugate for recurrent or metastatic cervical cancer, in Mainland China, Hong Kong, Macau, and Taiwan. The agreement includes an upfront payment of $30 million to Seagen, plus milestone payments and royalties shared with Genmab. With approximately 110,000 new cervical cancer cases annually in China and limited treatment options, Zai Lab aims to expand patient access and support ongoing clinical trials such as InnovaTV 301.
Zai Lab has secured exclusive rights to develop and commercialize TIVDAK, an FDA-approved antibody-drug conjugate, in Mainland China, Hong Kong, Macau, and Taiwan. The collaboration with Seagen involves a $30 million upfront payment, milestone payments, and shared royalties. TIVDAK addresses a significant unmet need in treating recurrent or metastatic cervical cancer, with 110,000 new cases annually in China. Ongoing clinical trials underpin the therapeutic potential of TIVDAK in various cancer treatments.